SMTL ID : 8y7l.1

Crystal Structure of Nur77 LBD in complex with N-(2'-(4-hydroxypiperidin-1-yl)-[4,4'-bipyridin]-2-yl)cinnamamide

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.68 Å

Oligo State

homo-dimer

Ligands

1 x 01: (~{E})-~{N}-[4-[2-(4-oxidanylpiperidin-1-yl)pyridin-4-yl]pyridin-2-yl]-3-phenyl-prop-2-enamide

01.1: 14 residues within 4Å: Chain B: H.12, S.15, G.16, P.17, R.90, Y.93, R.94, K.96, I.103, L.133, H.134, L.137, V.138, V.140 9 PLIP interactions: 9 interactions with chain B Hydrophobic interactions: B:R.90, B:R.90, B:Y.93, B:R.94, B:R.94, B:H.134 Hydrogen bonds: B:L.133, B:V.138 pi-Stacking: B:H.12

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Chen, J. et al., Discovery of a novel exceptionally potent and orally active Nur77 ligand NB1 with a distinct binding mode for cancer therapy. Acta Pharm Sin B (2024)

Release Date

2024-07-24

Peptides

Nuclear receptor subfamily 4immunitygroup A member 1: AB

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

Nuclear receptor subfamily 4immunitygroup A member 1